[1]World Health Organization. Multidrug and extensively drug-resistant TB (M/XDR-TB):2010 global report on surveillance and response[M/OL]. Geneva:WHO, 2010[2010-03-01].http://whqlibdoc.who.int/publications/2010/9789241599191_eng.pdf.[2]姜世闻,胡屹,张慧,等. 耐药结核病的流行简况. 中国防痨杂志, 2010, 32(6):351-353. [3]World Health Organization. Guidelines for the programmatic management of drug-resistant tuberculosis:Emergency update 2008[M/OL]. Geneva:WHO, 2008[2012-07-03].http://whqlibdoc.who.int/publications/2011/9789241501583_eng.pdf.[4]弭凤玲,王黎霞,李亮,等. 中国全球基金耐多药结核病项目阶段性实施结果分析. 中国防痨杂志, 2010, 32(11):700-704.[5]Green Light Committee. GLC annual report 2009[M/OL]. Geneva:WHO, 2010: 2429[2012-07-03]. http://whqlibdoc.who.int/hq/2010/WHO_HTM_TB_2010.14_eng.pdf.[6]Narita M, Alonso P, Lauzardo M, et al. Treatment experience of multidrug-resistant tuberculosis in Florida, 1994—1997. Chest, 2001, 120(2):343-348.[7]Munsiff SS, Ahuja SD, Li J, et al. Public-private collaboration for multidrug-resistant tuberculosis control in New York city. Int J Tuberc Lung Dis, 2006, 10(6):639-648.[8]Uffredi ML, TruffotPernot C, Dautzenberg B, et al. An intervention programme for the management of multidrug-resistant tuberculosis in France. Int J Antimicrob Agents, 2007, 29(4):434-439.[9]Long R, Chui L, Kakulphimp J, et al. Postsanatorium pattern of antituberculous drug resistance in the Canadian-born population of western Canada: effect of outpatient care and immigration. Am J Epidemiol, 2001, 153(9):903-911.[10]Seung KJ, Bai GH, Kim SJ, et al. The treatment of tuberculosis in South Korea. Int J Tuberc Lung Dis,2003,7(10):912-919.[11]Tupasi TE, Gupta R, Quelapio MI, et al. Feasibility and cost-effectiveness of treating multidrug-resistant tuberculosis: a cohort study in the Philippines. PLoS Med, 2006, 3(9):e352.[12]Leimane V, Leimans J. Tuberculosis control in Latvia: integrated DOTS and DOTS-plus programmes. Euro Surveill, 2006, 11(3):29-33.[13]Leimane V, Riekstina V, Holtz TH, et al. Clinical outcome of individualised treatment of multidrug-resistant tuberculosis in Latvia: a retrospective cohort study. Lancet, 2005, 365(9456): 318-326.[14]Mitnick C, Bayona J, Palacios E, et al. Community-based therapy for multidrug-resistant tuberculosis in Lima, Peru. N Engl J Med, 2003, 348(2):119-128.[15]Furin JJ, Mitnick CD, Shin SS, et al. Occurrence of serious adverse effects in patients receiving community-based therapy for multidrug-resistant tuberculosis. Int J Tuberc Lung Dis, 2001, 5(7):648-655.[16]Drobac PC, Mukherjee JS, Joseph JK, et al. Community-based therapy for children with multidrug-resistant tuberculosis. Pediatrics, 2006, 117(6):2022-2029.[17]Choi SS, Jazayeri DG, Mitnick CD, et al. Implementation and initial evaluation of a Web-based nurse order entry system for multidrug-resistant tuberculosis patients in Peru. Stud Health Technol Inform, 2004, 107(Pt 1):202-206.[18]Heller T, Lessells RJ, Wallrauch CG, et al. Community-based treatment for multidrug-resistant tuberculosis in rural KwaZulu-Natal, South Africa. Int J Tuberc Lung Dis, 2010, 14(4):420-426.[19]Nardell E, Dharmadhikari A. Turning off the spigot: reducing drug-resistant tuberculosis transmission in resource-limited settings. Int J Tuberc Lung Dis,2010,14(10):1233-1243.[20]Wilton P, Smith RD, Coast J, et al. Directly observed treatment for multidrug-resistant tuberculosis: an economic evaluation in the United States of America and South Africa. Int J Tuberc Lung Dis, 2001, 5(12):1137-1142.[21]World Health Organization. The global plan to stop tb 2011—2015: transforming the fight towards elimination of tuberculosis[M/OL]. Geneva:WHO, 2010[2010-10-13]. http://www.stoptb.org/assets/documents/global/plan/TB_GlobalPlanToStopTB2011-2015.pdf.[22]国务院办公厅. 医药卫生体制五项重点改革2011年度主要工作安排[EB/OL]. 北京:国务院办公厅,2011 [2011-02-13]. http://www.gov.cn/zwgk/2011-02/17/content_1805068.htm.[23]黄飞,王黎霞,成诗明,等. 医防合作对提高肺结核患者发现的影响. 中国防痨杂志,2010,32(7):8-12.[24]李尚伦. 耐多药肺结核防治筹资研究综述. 中国防痨杂志,2011,33(4):244-247.[25]Suárez PG, Floyd K, Portocarrero J, et al. Feasibility and cost-effectiveness of standardised second-line drug treatment for chronic tuberculosis patients: a national cohort study in Peru. Lancet, 2002, 359(9322):1980-1989. |